Olema Pharmaceuticals, Inc. Logo

Olema Pharmaceuticals, Inc.

A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.

OLMA | US

Overview

Corporate Details

ISIN(s):
US68062P1066
LEI:
Country:
United States of America
Address:
780 BRANNAN STREET, 94103 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Operating as Olema Oncology, the company is dedicated to transforming the standard of care, with a primary focus on breast cancer. Its lead product candidate, palazestrant (OP-1250), is a novel, investigational agent being developed for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Olema's mission is to develop more effective and tolerable medicines to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Olema Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Olema Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Olema Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
United States of America LBRX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden LPGO

Talk to a Data Expert

Have a question? We'll get back to you promptly.